Key result
Serial biomarker monitoring helps predict structural, functional, and clinical recovery in heart failure.
Why the study?
Heart failure recovery is associated with improved survival in HFrEF, making the identification of predictors important for guiding clinical practice and therapeutic innovation.
Does biomarker and imaging monitoring predict structural, functional, and clinical recovery in patients with acute and chronic heart failure?
Does biomarker and imaging monitoring predict structural, functional, and clinical recovery in patients with acute and chronic heart failure?
Biomarker and imaging monitoring, particularly NT-proBNP, can predict structural, functional, and clinical recovery in patients with heart failure.
Supports serial biomarker monitoring for HF recovery assessment; leaves open need for prospective trials on clinical outcomes.
Heart failure is a clinical syndrome caused by structural cardiac abnormalities that lead to increased intracardiac pressures and decreased cardiac output. Following cardiovascular insult or direct myocardial injury, neurohormonal activation triggers hemodynamic changes and cardiac remodeling to preserve cardiac output. While initially adaptive, cardiac remodeling eventually causes pathologic changes in cardiac structure that often compromise cardiac function. Reverse remodeling is the regression of abnormal cardiac chamber geometry and function after myocardial injury. In recent years, several classes of therapeutics have been associated with greater likelihood of reverse remodeling. Heart failure recovery and heart failure remission, terms encompassing the clinical correlates of reverse remodeling, have been associated with improved survival in patients with heart failure with reduced ejection. As such, identifying predictors of heart failure recovery can have important implications for guiding clinical practice and therapeutic innovation. This review addresses the role of biomarkers and imaging monitoring in predicting structural, functional, and clinical recovery in patients with acute and chronic heart failure.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2023) conducted a review in Heart failure. Biomarker and imaging monitoring was evaluated. Serial monitoring of biomarkers such as NT-proBNP, cardiac troponins, sST2, and galectin-3 can help predict structural, functional, and clinical recovery in patients with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: